Ausgewählte Publikationen

The infectivity and lytic activity of minute virus of mice wild-type and derived vector particles are strikingly different.
J Virol. 2005 Jan;79(1):289-98
Lang SI, Boelz S, Stroh-Dege AY, Rommelaere J, Dinsart C, Cornelis JJ.

Cancer therapy through autonomous parvovirus-mediated gene transfer.
Cornelis,JJ, Lang S, Stroh-Dege AY, Balboni G, Dinsart C, and Rommelaere J
Current Gene Therapy, 2004, Curr Gene Ther. 2004 Sep;4(3):249-61. Review

Vectors based on autonomous parvoviruses: novel tools to treat cancer ?
Cornelis JJ, Salomé N, Dinsart C, Rommelaere J
J Gene Med, 2004, 6:S193-S202

Oncolytic parvovirus H1 induces release of heat-shock protein HSP72 in susceptible human tumor cells but may not affect primary immune cells.
Moehler M, Zeidler M, Schede J, Rommelaere J, Galle PR, Cornelis JJ, and Heike M
Cancer Gene Therapy, 2003, 10:477-480.

Chimeric and pseudotyped parvoviruses minimize the contamination of recombinant stocks with replication competent viruses and identify a DNA sequence that restricts parvovirus H-1 in mouse cells.
Wrzesinski C, Tesfay L, Salomé N, Jauniaux J-C, Rommelaere J, Cornelis J, and Dinsart C
J Virol, 2003, 77:3851-3858.

Production of recombinant H-1 parvovirus stocks devoid of replication-competent viruses.
Brown CS, DiSumma F, Rommelaere J, Dege AY, Cornelis JJ, Dinsart C, and Spaan WJM
Human Gene Therapy, 2002, 13:2135-2145.

Suppression of metastatic hemangiosarcoma by a parvovirus MVMp vector transducing the IP-10 Chemokine into immunocompetent mice.
Giese NA, Raykov Z, De Martino L, Vecchi A, Sozzani S, Dinsart C, Cornelis JJ, and Rommelaere J
Cancer Gene Therapy, 2002, 9:432-442.

Effective infection, apoptotic cell killing and gene transfer of human hepatoma cells but not primary hepatocytes by parvovirus H1 and derived vectors.
Moehler M, Blechacz B, Weiskopf N, Zeidler M, Stremmel W, Rommelaere J, Galle PR, and Cornelis JJ
Cancer Gene Therapy, 2001, 8:158-167.

Potentiation of a recombinant oncolytic parvovirus by expression of apoptin.
Olijslagers S, Dege AY, Dinsart C, Voorhoeve M, Rommelaere J, Noteborn MHM, and Cornelis JJ
Cancer Gene Therapy, 2001, 8:958-965.

Transduction of human MCP-3 by a parvoviral vector induces leukocyte infiltration and reduces growth of human cervical carcinoma cell xenografts.
Wetzel K, Menten P, Opdenakker G, Van Damme J, Gröne HJ, Giese N, Vecchi A, Sozzani S, Cornelis JJ, Rommelaere J, and Dinsart, C.
J Gene Med, 2001, 3:326-337.

Autonomous parvovirus vectors.
Cornelis JJ, Haag A, Kornfeld C, Balboni G, Dege A, Neeb B, Dinsart C, and Rommelaere J
In: "Viral Vectors: Basic Science and Gene Therapy", eds. A. Cid-Arregui and A. Garcia-Carranca. BioTechniques Books, Eaton Publ., Natick, MA, 2000, pp. 97-115.

Autonomous parvovirus-based vectors: potential for the gene therapy of cancer.
Giese N, De Martino L, Haag A, Dinsart C, Cornelis JJ, and Rommelaere J
In: "Targeting of Drugs: Strategies for Gene Constructs and Delivery”, eds. G. Gregoriadis and B. McCormack. IOS Press, Amsterdam, 2000, pp. 34-52.

Highly efficient transduction and expression of cytokine genes into human tumor cells by means of autonomous parvovirus vectors generate antitumor responses in recipient mice.
Haag A, Menten P, Van Damme J, Dinsart C, Rommelaere J, and Cornelis JJ
Human Gene Therapy, 2000, 11:597-609.

Experimental induced infection with Autonomous Parvoviruses, Minute Virus of Mice and H-1, in the African Multimammate Mouse (Mastomys coucha).
Haag A, Wayss K, Rommelaere J, and Cornelis JJ
Comparative medicine, 2000, 50:613-621.

Cis-requirements for the efficient production of recombinant DNA vectors based on autonomous parvoviruses.
Kestler J, Neeb B, Struyf S, Van Damme J, Cotmore SF, D’Abramo A, Tattersall P, Rommelaere J, Dinsart C, and Cornelis JJ
Human Gene Therapy, 1999, 10:1619-1632.


Use of parvovirus for brain tumor therapy.
Rommelaere J, Cornelis J, Dinsart C, Schlehofer JR, Geletneky K, and Herrero Y Calle M. (deposited in 2003)
Application 10/426.709 (USA).

Parvovirus vectors and their use.
Rommelaere J, Tattersall P, D’Abramo A, Dinsart C, Cornelis JJ, Cotmore S. (deposited in 1999)
Application PCT/DE99/07755 (World)


Böelz, Stephanie (2002):
Characterization of recombinant parvoviruses in comparison with their corresponding normal viruses
Mannheim University of Applied Sciences, Germany


Lang, Susanne (2003):
Rekombinante Parvoviren in der Gentherapie von Krebs: Vektor Charakterisierung und Analyze der Wirksamkeit
Faculty of Science, Ruprecht-Karls-University, Heidelberg, Germany

Haag, Andreas (1999):
Tumortherapie mit natürlichen und rekombinanten autonomen Parvoviren im autologen Mastomys- und heterologen Nacktmaus-Modell.
Faculty of Veterinary, Leipzig University, Germany

Kestler, Jürgen (1997):
Entwicklung autonomer Parvoviren als neue Vektoren für die Gentherapie von Krebs.
Faculty of Pharmacy, Ruprecht-Karls University, Heidelberg, Germany

nach oben